Exenatide LAR

DRUG2 trials

Sponsors

AstraZeneca, University of Guadalajara

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 2

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

CompletedNCT00103935

AstraZenecaType 2 Diabetes Mellitus

Start: 2005-02-28End: 2005-10-31Updated: 2015-02-24

Phase 4

Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

University of GuadalajaraDiabetes Mellitus, Type 2

Start: 2017-11-17End: 2021-11-30Target: 30Updated: 2020-03-26

Related Papers

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.

2011-01-01111 citations